Clinical Trials Logo

Recurrent Cervical Cancer clinical trials

View clinical trials related to Recurrent Cervical Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04341883 Active, not recruiting - Clinical trials for Recurrent Cervical Cancer

Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer

Start date: November 13, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, phase II, multi-center clinical trial. Subjects can only enter this study after they meet the inclusion and exclusion criteria. All enrolled patients will receive the treatment with anti-PD-1 combined with albumin-bound paclitaxel, every 3 weeks, until progressive disease, initiation of new anti-tumour therapy, death, intolerable toxicity. Albumin-bound paclitaxel may be used for up to 6 cycles and anti-PD-1 for up to 2 years.